Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
27,461
archived clinical trials in
Hematology

S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
Eden Hospital Medical Center
mi
from
Castro Valley, CA
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
Eden Hospital Medical Center
mi
from
Castro Valley, CA
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
Kaiser Permanente - Irvine
mi
from
Irvine, CA
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
Kaiser Permanente - Irvine
mi
from
Irvine, CA
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
Kaiser Permanente-Cadillac
mi
from
Los Angeles, CA
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
Kaiser Permanente-Cadillac
mi
from
Los Angeles, CA
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
USC Norris Oncology/Hematology-Newport Beach
mi
from
Newport Beach, CA
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
USC Norris Oncology/Hematology-Newport Beach
mi
from
Newport Beach, CA
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
Kaiser Permanente Riverside
mi
from
Riverside, CA
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
Kaiser Permanente Riverside
mi
from
Riverside, CA
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
Sutter Cancer Centers Radiation Oncology Services-Roseville
mi
from
Roseville, CA
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
Sutter Cancer Centers Radiation Oncology Services-Roseville
mi
from
Roseville, CA
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
Kaiser Permanente-San Diego Mission
mi
from
San Diego, CA
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
Kaiser Permanente-San Diego Mission
mi
from
San Diego, CA
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
Kaiser Permanente-San Diego Zion
mi
from
San Diego, CA
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
Kaiser Permanente-San Diego Zion
mi
from
San Diego, CA
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
Kaiser Permanente-San Marcos
mi
from
San Marcos, CA
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
Kaiser Permanente-San Marcos
mi
from
San Marcos, CA
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
Palo Alto Medical Foundation-Sunnyvale
mi
from
Sunnyvale, CA
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
Palo Alto Medical Foundation-Sunnyvale
mi
from
Sunnyvale, CA
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
Gene Upshaw Memorial Tahoe Forest Cancer Center
mi
from
Truckee, CA
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
Gene Upshaw Memorial Tahoe Forest Cancer Center
mi
from
Truckee, CA
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
Sutter Cancer Centers Radiation Oncology Services-Vacaville
mi
from
Vacaville, CA
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
Sutter Cancer Centers Radiation Oncology Services-Vacaville
mi
from
Vacaville, CA
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
Smilow Cancer Hospital-Derby Care Center
mi
from
Derby, CT
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
Smilow Cancer Hospital-Derby Care Center
mi
from
Derby, CT
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
Smilow Cancer Hospital Care Center-Fairfield
mi
from
Fairfield, CT
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
Smilow Cancer Hospital Care Center-Fairfield
mi
from
Fairfield, CT
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
Medical Oncology and Hematology Group PC-Guilford
mi
from
Guilford, CT
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
Medical Oncology and Hematology Group PC-Guilford
mi
from
Guilford, CT
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
Smilow Cancer Hospital Care Center at Saint Francis
mi
from
Hartford, CT
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
Smilow Cancer Hospital Care Center at Saint Francis
mi
from
Hartford, CT
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
Yale-New Haven Hospital North Haven Medical Center
mi
from
North Haven, CT
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
Yale-New Haven Hospital North Haven Medical Center
mi
from
North Haven, CT
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
Smilow Cancer Hospital-Orange Care Center
mi
from
Orange, CT
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
Smilow Cancer Hospital-Orange Care Center
mi
from
Orange, CT
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
Charlotte Hungerford Hospital Center for Cancer Care
mi
from
Torrington, CT
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
Charlotte Hungerford Hospital Center for Cancer Care
mi
from
Torrington, CT
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
Smilow Cancer Hospital Care Center-Trumbull
mi
from
Trumbull, CT
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
Smilow Cancer Hospital Care Center-Trumbull
mi
from
Trumbull, CT
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
Smilow Cancer Hospital-Waterbury Care Center
mi
from
Waterbury, CT
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
Smilow Cancer Hospital-Waterbury Care Center
mi
from
Waterbury, CT
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
MedStar Washington Hospital Center
mi
from
Washington,
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
MedStar Washington Hospital Center
mi
from
Washington,
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
Hawaii Oncology Inc-Pali Momi
mi
from
'Aiea, HI
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
Hawaii Oncology Inc-Pali Momi
mi
from
'Aiea, HI
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
Pali Momi Medical Center
mi
from
'Aiea, HI
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
Pali Momi Medical Center
mi
from
'Aiea, HI
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
Hawaii Cancer Care Inc-POB II
mi
from
Honolulu, HI
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
Hawaii Cancer Care Inc-POB II
mi
from
Honolulu, HI
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
Hawaii Cancer Care Inc-Liliha
mi
from
Honolulu, HI
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
Hawaii Cancer Care Inc-Liliha
mi
from
Honolulu, HI
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
Hawaii Oncology Inc-Kuakini
mi
from
Honolulu, HI
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
Hawaii Oncology Inc-Kuakini
mi
from
Honolulu, HI
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
Kootenai Cancer Clinic
mi
from
Sandpoint, ID
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
Kootenai Cancer Clinic
mi
from
Sandpoint, ID
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
Western Illinois Cancer Treatment Center
mi
from
Galesburg, IL
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
Western Illinois Cancer Treatment Center
mi
from
Galesburg, IL
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
Radiation Oncology of Northern Illinois
mi
from
Ottawa, IL
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
Radiation Oncology of Northern Illinois
mi
from
Ottawa, IL
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
OSF Saint Francis Radiation Oncology at Pekin Cancer Treatment Center
mi
from
Pekin, IL
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
OSF Saint Francis Radiation Oncology at Pekin Cancer Treatment Center
mi
from
Pekin, IL
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
OSF Saint Francis Radiation Oncology at Peoria Cancer Center
mi
from
Peoria, IL
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
OSF Saint Francis Radiation Oncology at Peoria Cancer Center
mi
from
Peoria, IL
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
Valley Radiation Oncology
mi
from
Peru, IL
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
Valley Radiation Oncology
mi
from
Peru, IL
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
Central Illinois Hematology Oncology Center
mi
from
Springfield, IL
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
Central Illinois Hematology Oncology Center
mi
from
Springfield, IL
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
Southern Illinois University School of Medicine
mi
from
Springfield, IL
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
Southern Illinois University School of Medicine
mi
from
Springfield, IL
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
Springfield Clinic
mi
from
Springfield, IL
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
Springfield Clinic
mi
from
Springfield, IL
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
Cancer Care Specialists of Illinois-Swansea
mi
from
Swansea, IL
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
Cancer Care Specialists of Illinois-Swansea
mi
from
Swansea, IL
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
Reid Health
mi
from
Richmond, IN
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
Reid Health
mi
from
Richmond, IN
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
Iowa-Wide Oncology Research Coalition NCORP
mi
from
Des Moines, IA
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
Iowa-Wide Oncology Research Coalition NCORP
mi
from
Des Moines, IA
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
Siouxland Regional Cancer Center
mi
from
Sioux City, IA
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
Siouxland Regional Cancer Center
mi
from
Sioux City, IA
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
Cancer Center of Kansas, PA - Wichita
mi
from
Wichita, KA
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
Cancer Center of Kansas, PA - Wichita
mi
from
Wichita, KA
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
Wichita NCI Community Oncology Research Program
mi
from
Wichita, KA
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
Wichita NCI Community Oncology Research Program
mi
from
Wichita, KA
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
LSU Health Baton Rouge-North Clinic
mi
from
Baton Rouge, LA
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
LSU Health Baton Rouge-North Clinic
mi
from
Baton Rouge, LA
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
Louisiana Hematology Oncology Associates LLC
mi
from
Baton Rouge, LA
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
Louisiana Hematology Oncology Associates LLC
mi
from
Baton Rouge, LA
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
Mary Bird Perkins Cancer Center
mi
from
Baton Rouge, LA
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
Mary Bird Perkins Cancer Center
mi
from
Baton Rouge, LA
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
Medical Oncology LLC
mi
from
Baton Rouge, LA
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
Medical Oncology LLC
mi
from
Baton Rouge, LA
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
Mary Bird Cancer Center/Saint Tammany Parish
mi
from
Covington, LA
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
Mary Bird Cancer Center/Saint Tammany Parish
mi
from
Covington, LA
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
Mary Bird Perkins Cancer Center/Terrebonne General Medical Center
mi
from
Houma, LA
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
Mary Bird Perkins Cancer Center/Terrebonne General Medical Center
mi
from
Houma, LA
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
Central Maine Medical Center
mi
from
Lewiston, ME
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
Central Maine Medical Center
mi
from
Lewiston, ME
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
Michigan Cancer Research Consortium NCORP
mi
from
Ann Arbor, MI
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
Michigan Cancer Research Consortium NCORP
mi
from
Ann Arbor, MI
Click here to add this to my saved trials